紫杉醇与长春瑞滨联合顺铂治疗晚期非小细胞肺癌  

Clinical study on combined chemotherapy of paclitaxel or navelbine plus cisplatin for advanced non-small cell lung cancer

作　　者：陈建华[1] 肖华伍[1] 欧阳周[1] 

机构地区：[1]湖南省肿瘤医院内科,湖南长沙410013

出　　处：《世界肿瘤杂志》2007年第3期174-175,178,共3页Tumour Journal of the World

摘　　要：目的比较紫杉醇（T）及长春瑞滨（N）联合顺铂（P）治疗Ⅲb／Ⅳ期非小细胞肺癌（NSCLC）的疗效、毒副反应。方法对晚期非小细胞肺癌48例，分别应用TP和NP方案化疗，治疗2周期评价疗效和毒副反应。结果44例可评价疗效，两组近期有效率分别为45．0％和46．8％，无显著性差异（x^2=2．25，P=0．512）。两组间主要毒性反应为消化道反应和骨髓抑制，其Ⅲ、Ⅳ度反应发生率无统计学差异（P〈0．05），TP组过敏性休克2例，心衰2例，但对症处理后均恢复，无死亡病例。NP组无过敏性休克和心脏毒性反应。结论两方案的近期疗效和血液毒性及消化道毒性反应相近，但应用紫杉醇时应注意过敏性休克和心衰的发生，一旦发生，如及时对症处理，一般无严重后果。两方案均为目前非小细胞肺癌较好的治疗方案。Objective To compare the efficacy and toxicity of combined chemotherapy of paclitaxel or navelbine plus cisplafin for advanced non-small cell lung cancer （NSCLC）. Methods Forty-eight cases of advance （stage Ⅲb-Ⅳ） NSCLC were treated with the regimen of paclitaxel（T）or navelbine（N） plus cisplatin （P）, and forty-four cases finished two cycles. Results The response rate of the group TP and NP were 45.0% vs 46.8%. The main toxicity of two groups was myelosuppression, and there were two cases allergy and two heart fail in the TP group. Conclusions There were no significant discrepancy of response rate and the toxicity in the group TP and NP. The regimens are benefit for NSCLC.

关 键 词：非小细胞肺癌 紫杉醇 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]